|Bid||4.91 x 1000|
|Ask||6.50 x 400|
|Day's range||4.96 - 5.21|
|52-week range||4.60 - 27.98|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.83|
Last week, Vivek Ramaswamy's biggest bet, on the Alzheimer's drug being developed by Axovant Sciences, failed. This morning, one of his smaller ones came through: a treatment for uterine fibroids being tested by Myovant, another company started by Ramaswamy's vehicle, Roivant.
Biotech has had a great year, with the SPDR S&P Biotech ETF (XBI) up nearly 50% since the start of 2017. Yet Barron’s has argued that the biotech sector is still undervalued, given major advances on the ...
A sudden collapse in Axovant Sciences Ltd.’s stock price after the company’s Alzheimer’s drug failed a pivotal clinical trial has stung some big-name Wall Street investors.
Biotech stocks are on fire this year, and a key event this week could spark a massive move in one name that’s already up more than 100 percent.
NEW YORK, April 28 - Orphan drug developer Biohaven Pharmaceuticals' proposed US$133m IPO represents the largest attempt at a biotech new listing this year. Morgan Stanley, Piper Jaffray and Barclays are ...
** Shares of Swiss biotech AC Immune down 6.7 pct to $10.79 in light premarket trading on block sale ** Sources say Jefferies re-offered 1.9 mln shares at $11, roughly 5-pct discount to stock's $11.57 ...
PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Atul Pande, M.D., as the Company’s Chief Medical Officer. In this new role, Dr. Pande will oversee all clinical operations across PureTech Health’s pipeline and work closely with the team to de-risk and advance opportunities that hold the most potential for patients. Dr. Pande commented: “I am proud and delighted to join this stellar team and hope to be instrumental in enabling the launch of some of the truly innovative medicines in the PureTech Health pipeline.